November 9, 2015 Morayea Pindziak

Alliance Presents Insights into Orphan Drug and Rare Disease Sector, Highlights Pricing Trends, Challenges and Solutions

6th Annual World Orphan Drug Conference, Nov. 11-13, 2015, Geneva


SOMERSET, N.J. / GENEVA — November 9, 2015 — Alliance Life Sciences, a leading global life sciences consultancy and technology provider, announces that Alan Crowther, CEO, Alliance Life Sciences, and Carina Schey, consultant health economist and researcher at the University of Groningen, will present at the 6th Annual World Orphan Drug Conference, Nov. 11-13, 2015, Starling Geneva Hotel and Conference Center, Geneva. The joint presentation will focus on the orphan drug and rare disease sector, articulating pricing trends, challenges and potential solutions.

“We will share information and key developments surrounding orphan drug pricing trends, provide a snapshot of the pricing models available today, and outline some of the challenges that manufacturers are facing, along with suggestions on what the industry needs to consider in orphan drug pricing,” says Crowther, veteran in commercial pharmaceutical with extensive experience in pricing. “Carina brings to this discussion many years of experience in both the pharmaceutical and clinical pharmacy sectors, and draws upon her expertise to provide guidance on how to demonstrate the value of orphan drugs.”

The World Orphan Drug Conference brings together a wide range of stakeholders and influencers in the orphan drug and rare disease sector. Alliance Life Sciences will serve as co-sponsor of the conference, Europe’s leading event for orphan drug developers, patient groups and payers.

“This event continues to be a pivotal opportunity for developing strategies, encouraging advocacy, and partnering within the rare disease community,” Crowther adds. “We are committed to sharing relevant, well-researched information at the cusp of global and regional trends in the orphan drug space.”